Detalles de la búsqueda
1.
Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
Leuk Lymphoma
; 61(13): 3188-3197, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32762271
2.
Improvement of fatigue, physical functioning, and well-being among patients with severe impairment at baseline receiving ibrutinib in combination with bendamustine and rituximab for relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma in the HELIOS study.
Leuk Lymphoma
; 59(9): 2075-2084, 2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-29295653
3.
Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus.
Leuk Lymphoma
; 58(12): 2824-2832, 2017 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-28556689
Resultados
1 -
3
de 3
1
Próxima >
>>